Gadodiamide
Paramagnetic Contrast Agent — VARIOUS
Also known as: omniscan
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Gadodiamide is a drug in the Paramagnetic Contrast Agent class catalogued in DrugCentral. It was first approved by the FDA in 1993. Its mechanism of action is classified as Magnetic Resonance Contrast Activity. Recorded indications include Magnetic resonance imaging.
- Drug class: Paramagnetic Contrast Agent.
- Mechanism of action: Magnetic Resonance Contrast Activity.
- Indications: Magnetic resonance imaging.
- ATC code: V08CA03 (Paramagnetic contrast media).
- Molecular formula: C16H26GdN5O8; molecular weight 573.66 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Magnetic resonance imaging
Mechanism & targets
| Mechanism of action (MoA) | Magnetic Resonance Contrast Activity |
|---|---|
| Established pharmacologic class | Paramagnetic Contrast Agent |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1993-01-08 | FDA | — | GE HEALTHCARE |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
V08CA03 | VARIOUS › CONTRAST MEDIA › MAGNETIC RESONANCE IMAGING CONTRAST MEDIA › Paramagnetic contrast media |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Nephrogenic systemic fibrosis | 5411.0 |
| Skin hypertrophy | 843.7 |
| Skin induration | 818.9 |
| Skin tightness | 694.0 |
| Skin fibrosis | 461.5 |
| Joint contracture | 399.5 |
| Fibrosis | 363.8 |
| Scar | 269.9 |
| Magnetic resonance imaging head abnormal | 237.9 |
| Biopsy brain abnormal | 232.8 |
| Emotional distress | 230.4 |
| Skin hyperpigmentation | 215.5 |
Chemical structure
| Molecular formula | C16H26GdN5O8 |
|---|---|
| Molecular weight | 573.66 g/mol |
| CAS number | 131410-48-5 |
| InChIKey | — |
| PubChem CID | 153921 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Gadodiamide used for?
DrugCentral lists the following indications for Gadodiamide: Magnetic resonance imaging.
How does Gadodiamide work?
Gadodiamide is classified as Magnetic Resonance Contrast Activity.
When was Gadodiamide first approved?
Gadodiamide was first approved by the FDA in 1993.
What drug class does Gadodiamide belong to?
Gadodiamide is in the Paramagnetic Contrast Agent class.
What is the chemical formula of Gadodiamide?
Gadodiamide has the molecular formula C16H26GdN5O8 and a molecular weight of 573.66 g/mol.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4494 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200346 — compound record and bioactivity
- PubChem CID 153921 — chemical identifiers
- DrugBank DB00225 — drug record
- FDA UNII 84F6U3J2R6 — substance identity
- DailyMed: FDA labels for Gadodiamide — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.